Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Kenvue $4.37 billion IPO
The carve-out of the former Johnson & Johnson consumer health business is the largest U.S. IPO since November 2021
Privia Health Group $936 million secondary offering
We advised Privia on the registered secondary offering
DexCom $1.25 billion convertible notes offering and capped call transactions
The 0.375% convertible senior notes are due 2028
Cellular Biomedicine Group CAR-T collaboration and license agreement with Janssen
We are advising Cellular Biomedicine Group on the transaction
Invacare chapter 11 plan confirmed
We advised the prepetition term loan agent and escrow agent on the transaction
MedSci Healthcare Holdings HK$608 million IPO
We advised MedSci on its IPO and HKEX listing
IDEAYA Biosciences $201 million equity offering
The common stock is listed on the Nasdaq Global Select Market
Diagnósticos da América R$1.7 billion equity offering
The common shares and the warrants are listed on the São Paulo Stock Exchange
Gamida Cell $23 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
AN2 Therapeutics $100 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market